Transcell Biologics raises funds from Indian Angel Network

Indian Angel Network (IAN), a network of angel investors who invest in early-stage businesses, has invested an undisclosed amount in Hyderabad-based healthcare start-up Transcell Biologics in a round led by angel investor Sanjay Jesrani, said IAN on Thursday. Jesrani will join the board of the company.

The company plans to use the investment to develop products out of stem cell based platforms in both the therapeutic and non-therapeutic areas.

The company was started in 2009 by Dr. Subhadra Dravida who has 16 years of experience in stem cell research.

The start-up develops transformative stem cell based products portfolio and is creating repository of India-specific patient derived tissues for research and development. This will be used towards advancements in modern adult stem cell technology based drug discovery in oncology and brain diseases.

Globally, stem cell therapy is integrated to treat a number of chronic and incurable diseases such as blood cancer and thalassemia.

“Transcell Biologics provides end-to-end solution offerings in stem cell bio banking and ensures quality processing and presentations for the intended applications. We are built on the rock bed of home grown technologies with intellectual property as our business asset since inception with focus on clinical translation,” said Dravida, founder and chief executive officer of Transcell Biologics.

The company had commercialized home-grown stem cell banking vertical in 2011. “With the advancement in technology, newer players are entering the Indian market with an aim to not just to preserve precious lives of the coming generation but also for the regenerative medicine space. Transcell Biologics is one such company who wants to help the needy patient population with the support of their home grown technologies translations. The company has phenomenal amount of research assets in this domain,” said Jesrani.

Also read:

China’s WuXi PharmaTech tapping banks for $1.5b IPO for biologics arm

Warburg Pincus nets $425.7m for China Biologic Products stake sale

Indonesia: Kalbe Farma, Kimia Farma constructing bio-pharmacy raw material plants

 This story was first published on